Eli Lilly & Co.’s $62 million settlement with 32 states and the District of Columbia over off-label Zyprexa marketing comes with an agreement requiring, among other things, that the company furnish those state AGs with a list of all healthcare professionals paid more than $100 for promotional speaking and consulting in the US.
Researches involved in the litigation against Vioxx claim the product’s ADVANTAGE trials were based on marketing objectives rather than scientific rigor.
New York Gov. David Paterson is proposing legislation that would impose a ban on gifts to doctors and require physicians making presentations at CME events to disclose any financial relationships with drug companies.
Wyeth and Elan have suspended a clinical study of their jointly developed Alzheimer’s vaccine ACC-001 after a patient receiving the treatment was hospitalized for nearly two weeks with skin ulcers.
Crestor to benefit as ENHANCE smoke clears: survey
Expect AstraZeneca’s Crestor to emerge as the big winner in the aftermath of Merck/Schering Plough’s Vytorin debacle, primary care physicians (PCPs) said.
Georgia Tech researchers aim to improve trials outcomes, boost Rx compliance with sensor necklace
Researchers from the Georgia Institute of Technology (GIT) have devised an innovative medication monitoring device that could prove to be a useful tool for pharma researchers and marketers of the future.
GSK avoids UK prosecution over antidepressant clinical trials data
The UK’s drugs regulatory agency said it would not prosecute GlaxoSmithKline (GSK) for allegedly withholding clinical trials data related to its antidepressant Seroxat (paroxetine), sold in the US under the brand name Paxil.
Study claims antidepressants benefit only small portion of patients
A new study of prescription antidepressants published this week suggests the drugs may be no more effective than placebo in treating the most common forms of depression.
Schering-Plough posts Q4 loss as Congress eyes web posts in Vytorin probe
Schering-Plough posted a fourth quarter loss on charges related to its acquisition of Organon and said it was ready to take action if sales of Vytorin and Zetia decline significantly.
There was good news and bad news for Merck/Schering-Plough following their release of long-delayed and disappointing data from the ENHANCE trial, which found no advantage for Vytorin over simvastatin in retarding the progress of atherosclerosis.